Reimbursement Support

BPL is committed to helping you find support for your patients

BPL provides reimbursement support for patients receiving COAGADEX. This support includes:

  • Patient-specific benefit verifications
  • Payer coverage and coding research
  • Assistance with claims questions (including information on coding and billing)
  • Claims tracking
  • Assistance with prior authorizations
  • Appeal support for denied prior authorization or claims

Call:
844-4BPLUSA
(844-427-5872)

Quick Reference Coding and Billing Guide

COAGADEX NDC Numbers

Fill Size NDC Number
250 IU Range 64208-7752-1
500 IU Range 64208-7753-1

COAGADEX HCPCS Code

HCPCS Description
J7175 Injection, factor x, (human), 1 i.u.

COAGADEX ICD-10 Diagnosis Codes

ICD-10-CM Code1 Description
D68.8 OTHER SPECIFIED COAGULATION DEFECTS
D68.9 COAGULATION DEFECT, UNSPECIFIED
D68.2 HEREDITARY DEFICIENCY OF OTHER CLOTTING FACTORS

COAGADEX CPT Codes

CPT Code Description
Home Infusion:
99601 Home infusion/specialty drug administration, per visit (up to 2 hours)
99602 Home infusion/specialty drug administration, per visit each additional hour (list separately in addition to primary procedure)
Hospital Infusion:
96374 Therapeutic, prophylactic or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug
96376 Intravenous push, single or initial substance/drug; each additional sequential intravenous push of the same substance/drug provided in a facility (list separately in addition to code for primary procedure)

Reference: 1. Centers for Medicare & Medicaid Services. 2017 ICD-10-CM and GEMs. https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CM-and-GEMs.html. Accessed May 12, 2017.

Indications and Usage for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

Limitation of Use

Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.

Contraindication for COAGADEX

COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.

Important Safety Information for COAGADEX

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ‚Č•5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.